中国女性乳腺癌筛查与早诊早治指南(2021,北京)

乳腺癌是中国女性最常见的恶性肿瘤,发病率位居中国女性恶性肿瘤首位。国家癌症中心受国家卫生健康委员会疾病预防控制局委托,根据《世界卫生组织指南制定手册》制定本部女性乳腺癌筛查与早诊早治指南。制作系统评价流程参考Cochrane协作网的方法,证据质量与推荐强度的分级采用推荐意见分级的评估、制定及评价方法,并根据国际实践指南报告规范条目进行报告。在系统评价结果的基础上,结合中国国情,综合考虑了证据的利弊、证据的质量、筛查经济成本、多学科临床调查对象的反馈和面对面的专家共识意见,针对乳腺癌筛查与早诊早治中适宜人群、技术流程等进行循证推荐,旨在规范女性乳腺癌筛查与早诊早治实践,提升中国女性乳腺癌防控效果。

China Guideline for the Screening and Early Detection of Female Breast Cancer (2021,Beijing)

Breast cancer ranks first in the incidence of female cancer in China. The guideline is commissioned and directed by the Bureau of Disease Control and Prevention of National Health Commission. Under the initiation of the National Cancer Center of China,a multidisciplinary guideline development group was established. The development of the guideline followed the principles and methods recommended by the World Health Organization. Among them,the method of Cochrane Collaboration is used to develop the systematic evaluation,GRADE method is adopted for the classification of evidence quality and recommendation strength,and the report is made according to the Reporting Items for Practice Guidelines in Healthcare item. Based on the most up-todate evidence in breast cancer screening worldwide,as well as China’s national conditions and practical experience in breast cancer screening,the guideline would include the screening population and technology,in order to enhance the effectiveness of female breast cancer screening prevention and control in China.